Valuation: Adocia

Market Cap 4.2Cr 4.73Cr 3.92Cr 3.57Cr 6.74Cr 454.3Cr 6.8Cr 47Cr 18Cr 232.24Cr 18Cr 17Cr 745.35Cr P/E 2026 *
-2.62x
P/E 2027 * 3.1x
Enterprise Value 4.64Cr 5.22Cr 4.33Cr 3.95Cr 7.44Cr 501.91Cr 7.51Cr 52Cr 20Cr 256.58Cr 20Cr 19Cr 823.46Cr EV / Sales 2026 *
-
EV / Sales 2027 * 1.61x
Free-Float
93.92%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 11/05/2023
Director of Finance/CFO - 23/09/2024
Chief Tech/Sci/R&D Officer - 01/12/2014
Director TitleAgeSince
Director/Board Member 55 19/04/2013
Chairman 57 -
Director/Board Member 61 11/05/2023
Change 5-day change 1-year change 3-year change Capi.($)
-5.93%-12.50% - - 4.73Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-3.11%-3.53%+21.92%+74.60% 5.74TCr
+0.89%-0.63%+4.28%+34.51% 4.76TCr
+0.36%+0.81%+352.17%+689.61% 4.43TCr
-0.96%-4.50%+26.36%+33.18% 4.25TCr
-0.20%-0.77%+3.74%+100.60% 4.07TCr
-0.54%+2.93%+9.31%+50.41% 3.1TCr
-2.68%+2.92%+29.63%+19.50% 2.85TCr
+0.05%-1.64%-7.28%-14.06% 2.43TCr
Average -0.80%-0.47%+54.39%+120.28% 4.34TCr
Weighted average by Cap. +0.12%-0.69%+58.77%+129.91%

Financials

2026 *2027 *
Net sales - 4.49Cr 5.05Cr 4.19Cr 3.82Cr 7.2Cr 485.44Cr 7.27Cr 51Cr 20Cr 248.16Cr 19Cr 19Cr 796.45Cr
Net income -1.6Cr -1.8Cr -1.49Cr -1.36Cr -2.57Cr -173.11Cr -2.59Cr -18Cr -7Cr -88Cr -6.76Cr -6.61Cr -284.02Cr -4.43Cr -4.99Cr -4.14Cr -3.77Cr -7.11Cr -479.61Cr -7.18Cr -50Cr -19Cr -245.18Cr -19Cr -18Cr -786.88Cr
Net Debt 44L 49.52L 41.07L 37.43L 70.59L 48Cr 71.25L 4.97Cr 1.93Cr 24Cr 1.86Cr 1.82Cr 78Cr 3.02Cr 3.4Cr 2.82Cr 2.57Cr 4.84Cr 326.5Cr 4.89Cr 34Cr 13Cr 166.91Cr 13Cr 12Cr 535.67Cr
Logo Adocia
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
73
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-